[The future of oncohematology]

Area of Science:

• Oncohematology
• Medical Oncology
• Hematology

Context:

• Significant evolution in the understanding and treatment of oncohematological diseases over the last four decades.
• Shift from palliative care to chemotherapy (CT) as a primary treatment modality.
• Discovery and application of key drugs including antifolics, corticoids, and antipurine agents.

Purpose:

• To review the historical advancements and current status of chemotherapy and other treatment modalities in oncohematological affections.
• To highlight the impact of chemotherapy on survival rates in acute lymphoblastic leukemia (ALL) and acute myeloblastic leukemia (AML).
• To discuss the potential and challenges of gene therapy and immunotherapy in treating leukemias and lymphomas.

Summary:

• Chemotherapy has dramatically improved survival rates for acute lymphoblastic leukemia (ALL) and Hodgkin's disease, with survival rates reaching 50% and over 80% respectively.
• While chemotherapy results for acute myeloblastic leukemia (AML) are less spectacular, survival rates have reached 25% overall and 40-50% in young adults.
• Allogeneic transplant requires careful patient-specific evaluation; gene therapy holds potential but faces vector and gene selection challenges.
• Immunotherapy, with or without chemotherapy, represents a promising new frontier in oncohematological treatment.

Impact:

• Chemotherapy has transformed outcomes for patients with leukemia and lymphomas, saving lives and improving prognoses.
• Ongoing research in gene therapy and immunotherapy suggests potential for even greater therapeutic advancements in the future.
• The transition from palliative care to effective CT has redefined the treatment landscape for hematological cancers.